Regenerative Medical Technology Group Inc. RMTG revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Regenerative Medical Technology Group Inc. reported revenue across 5 products and services; the largest, Global Stem Cells Group, was $5.1M.
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Global Stem Cells Group$5.1Mshare n/ano prior
- Product Supplies$2.02Mshare n/a+15.8% yoy
- Patient Procedures$1.87Mshare n/a+36.7% yoy
- Training$1.13Mshare n/a+39.0% yoy
- Equipments$75.8Kshare n/a-57.2% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Global Stem Cells Group$2.64Mshare n/ano prior
- Product Supplies$1.27Mshare n/a+102.2% yoy
- Training$772Kshare n/a+432.7% yoy
- Patient Procedures$600Kshare n/a+1.3% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.